3-weekly cisplatin or weekly cisplatin for squamous cell carcinoma of head and neck

Bookmark and Share
Published: 12 Jun 2020
Views: 571
Dr Naomi Kiyota - Kobe University, Kobe, Japan

Dr Naomi Kiyota speaks to ecancer in an online interview for the ASCO virtual meeting 2020 about the JCOG1008 study which compares 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck.

Kiyota explains that weekly cisplatin is non-inferior to an every-3-weeks dose as part of chemoradiotherapy regimen for certain patients, but compliance to this regimen often is insufficient due to high-dose-related toxicities.